Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant vs Postoperative Chemotherapy for Resectable Locally Advanced Colon Cancer
NCT02882269Phase 3Unknown
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Dec 2016
- Primary completion
- Dec 2021
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
01
Overview
Phase 3, randomised, open-label trial of oxaliplatin, fluorouracil, capecitabine and irinotecan in colon cancer (2 arms), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Disease-Free Survival at 3 years. Status: unknown.
02
Drugs
oxaliplatinfluorouracilcapecitabineirinotecan
03
Conditions
colon cancer
Beyond the preview
Go deeper on NCT02882269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02882269.